Clustered Computing for Political Science

http://deepblue.lib.umich.edu/bitstream/2027.42/116267/1/tpm04.pd

Observational evidence for cosmological coupling of black holes and its implications for an astrophysical source of dark energy

Observations have found black holes spanning ten orders of magnitude in mass across most of cosmic history. The Kerr black hole solution is however provisional as its behavior at infinity is incompatible with an expanding universe. Black hole models with realistic behavior at infinity predict that the gravitating mass of a black hole can increase with the expansion of the universe independently of accretion or mergers, in a manner that depends on the black hole's interior solution. We test this prediction by considering the growth of supermassive black holes in elliptical galaxies over $0<z\lesssim2.5$. We find evidence for cosmologically coupled mass growth among these black holes, with zero cosmological coupling excluded at 99.98% confidence. The redshift dependence of the mass growth implies that, at $z\lesssim7$, black holes contribute an effectively constant cosmological energy density to Friedmann's equations. The continuity equation then requires that black holes contribute cosmologically as vacuum energy. We further show that black hole production from the cosmic star formation history gives the value of $\Omega_{\Lambda}$ measured by Planck while being consistent with constraints from massive compact halo objects. We thus propose that stellar remnant black holes are the astrophysical origin of dark energy, explaining the onset of accelerating expansion at $z \sim 0.7$.Comment: 10 pages, 3 figures, published in ApJ Letter

A Preferential Growth Channel for Supermassive Black Holes in Elliptical Galaxies at z ≲ 2

The assembly of stellar and supermassive black hole (SMBH) mass in elliptical galaxies since z ∼ 1 can help to diagnose the origins of locally observed correlations between SMBH mass and stellar mass. We therefore construct three samples of elliptical galaxies, one at z ∼ 0 and two at 0.7 ≲ z ≲ 2.5, and quantify their relative positions in the MBH−M * plane. Using a Bayesian analysis framework, we find evidence for translational offsets in both stellar mass and SMBH mass between the local sample and both higher-redshift samples. The offsets in stellar mass are small, and consistent with measurement bias, but the offsets in SMBH mass are much larger, reaching a factor of 7 between z ∼ 1 and z ∼ 0. The magnitude of the SMBH offset may also depend on redshift, reaching a factor of ∼20 at z ∼ 2. The result is robust against variation in the high- and low-redshift samples and changes in the analysis approach. The magnitude and redshift evolution of the offset are challenging to explain in terms of selection and measurement biases. We conclude that either there is a physical mechanism that preferentially grows SMBHs in elliptical galaxies at z ≲ 2, or that selection and measurement biases are both underestimated, and depend on redshift

Molecular Gas Heating, Star Formation Rate Relations, and AGN Feedback in Infrared-Luminous Galaxy Mergers

We examine the origin of molecular gas heating in a sample of 42 infrared-luminous galaxies at z<0.3 by combining two sets of archival data: first, integrated CO line luminosities in the 1–0 and 5–4 through 13–12 transitions; second, results from radiative transfer modelling that decompose their bolometric emission into starburst, AGN, and host galaxy components. We find that the CO 1–0 and 5–4 through 9–8 lines primarily arise via radiative heating in the starburst and the host galaxy. In contrast, the CO 10–9 through 13–12 lines may arise primarily in the starburst and AGN, with an increasing contribution from mechanical heating and shocks. For the sample as a whole, we find no evidence that AGN luminosity affects the heating of molecular gas by star formation. However, for starbursts with low initial optical depths, a more luminous AGN may reduce the efficiency of starburst heating of the CO 5–4 and above lines, consistent with negative AGN feedback

Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform.

BACKGROUND: Hydroxychloroquine has been shown to inhibit entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into epithelial cells in vitro, but clinical studies found no evidence of reduced mortality when treating patients with COVID-19. We aimed to evaluate the effectiveness of hydroxychloroquine for prevention of COVID-19 mortality, as opposed to treatment for the disease. METHODS: We did a prespecified observational, population-based cohort study using national primary care data and linked death registrations in the OpenSAFELY platform, which covers approximately 40% of the general population in England, UK. We included all adults aged 18 years and older registered with a general practice for 1 year or more on March 1, 2020. We used Cox regression to estimate the association between ongoing routine hydroxychloroquine use before the COVID-19 outbreak in England (considered as March 1, 2020) compared with non-users of hydroxychloroquine and risk of COVID-19 mortality among people with rheumatoid arthritis or systemic lupus erythematosus. Model adjustment was informed by a directed acyclic graph. FINDINGS: Between Sept 1, 2019, and March 1, 2020, of 194 637 people with rheumatoid arthritis or systemic lupus erythematosus, 30 569 (15·7%) received two or more prescriptions of hydroxychloroquine. Between March 1 and July 13, 2020, there were 547 COVID-19 deaths, 70 among hydroxychloroquine users. Estimated standardised cumulative COVID-19 mortality was 0·23% (95% CI 0·18 to 0·29) among users and 0·22% (0·20 to 0·25) among non-users; an absolute difference of 0·008% (-0·051 to 0·066). After accounting for age, sex, ethnicity, use of other immunosuppressive drugs, and geographical region, no association with COVID-19 mortality was observed (HR 1·03, 95% CI 0·80 to 1·33). We found no evidence of interactions with age or other immunosuppressive drugs. Quantitative bias analyses indicated that our observed associations were robust to missing information for additional biologic treatments for rheumatological disease. We observed similar associations with the negative control outcome of non-COVID-19 mortality. INTERPRETATION: We found no evidence of a difference in COVID-19 mortality among people who received hydroxychloroquine for treatment of rheumatological disease before the COVID-19 outbreak in England. Therefore, completion of randomised trials investigating pre-exposure prophylactic use of hydroxychloroquine for prevention of severe outcomes from COVID-19 are warranted. FUNDING: Medical Research Council

Observational Evidence for Cosmological Coupling of Black Holes and its Implications for an Astrophysical Source of Dark Energy

Observations have found black holes spanning 10 orders of magnitude in mass across most of cosmic history. The Kerr black hole solution is, however, provisional as its behavior at infinity is incompatible with an expanding universe. Black hole models with realistic behavior at infinity predict that the gravitating mass of a black hole can increase with the expansion of the universe independently of accretion or mergers, in a manner that depends on the black hole’s interior solution. We test this prediction by considering the growth of supermassive black holes in elliptical galaxies over 0 < z ≲ 2.5. We find evidence for cosmologically coupled mass growth among these black holes, with zero cosmological coupling excluded at 99.98% confidence. The redshift dependence of the mass growth implies that, at z ≲ 7, black holes contribute an effectively constant cosmological energy density to Friedmann’s equations. The continuity equation then requires that black holes contribute cosmologically as vacuum energy. We further show that black hole production from the cosmic star formation history gives the value of ΩΛ measured by Planck while being consistent with constraints from massive compact halo objects. We thus propose that stellar remnant black holes are the astrophysical origin of dark energy, explaining the onset of accelerating expansion at z ∼ 0.7

Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis

AbstractBackgroundEarly descriptions of the coronavirus outbreak showed a lower prevalence of asthma and COPD than was expected for people diagnosed with COVID-19, leading to speculation that inhaled corticosteroids (ICS) may protect against infection with SARS-CoV-2, and development of serious sequelae. We evaluated the association between ICS and COVID-19 related death using linked electronic health records in the UK.MethodsWe conducted cohort studies on two groups of people (COPD and asthma) using the OpenSAFELY platform to analyse data from primary care practices linked to national death registrations. People receiving an ICS were compared to those receiving alternative respiratory medications. Our primary outcome was COVID-19 related death.FindingsWe identified 148,588 people with COPD and 817,973 people with asthma receiving relevant respiratory medications in the four months prior to 01 March 2020. People with COPD receiving ICS were at a greater risk of COVID-19 related death compared to those receiving a long-acting beta agonist (LABA) and a long-acting muscarinic antagonist (LAMA) (adjusted HR = 1.38, 95% CI = 1.08 – 1.75). People with asthma receiving high dose ICS were at an increased risk of death compared to those receiving a short-acting beta agonist (SABA) only (adjusted HR = 1.52, 95%CI = 1.08 – 2.14); the adjusted HR for those receiving low-medium dose ICS was 1.10 (95% CI = 0.82 – 1.49). Quantitative bias analyses indicated that an unmeasured confounder of only moderate strength of association with exposure and outcome could explain the observed associations in both populations.InterpretationThese results do not support a major role of ICS in protecting against COVID-19 related deaths. Observed increased risks of COVID-19 related death among people with COPD and asthma receiving ICS can be plausibly explained by unmeasured confounding due to disease severity.FundingThis work was supported by the Medical Research Council MR/V015737/1.</jats:sec